医学
养生
相伴的
随机对照试验
化疗
临床终点
内科学
外科
泌尿科
作者
F. Mornex,Luc Thomas,Peter Mohr,Axel Hauschild,Michèle M Delaunay,Thierry Lesimple,Wolfgang Tilgen,B. Bui,Bernard Guillot,Jens Ulrich,S. Bourdin,Mirerille Mousseau,Didier Cupissol,Marie-Edith Bonneterre,C. De Gislain,R.J. Bensadoun,M Clavel
出处
期刊:Melanoma Research
[Lippincott Williams & Wilkins]
日期:2003-02-01
卷期号:13 (1): 97-103
被引量:155
标识
DOI:10.1097/00008390-200302000-00016
摘要
The main objective of this prospective multicentre randomized phase III study was to compare a combined regimen of fotemustine plus whole brain irradiation with fotemustine alone in terms of cerebral response and time to cerebral progression in patients with melanoma cerebral metastases. Seventy-six patients were randomized to receive either fotemustine (arm A, n = 39) or fotemustine plus whole brain irradiation (arm B, n = 37). Fotemustine was administered intravenously at 100 mg/m(2) on days 1, 8 and 15, followed by a 5 week rest period, then every 3 weeks in non-progressive patients. In arm B, concomitant whole brain irradiation was performed at a total dose of 37.5 Gy (2.5 Gy/day on days 1-5 for three consecutive weeks). Although patients who received fotemustine alone had worse prognostic factors, there was no significant difference in cerebral response (arm A, 7.4%, arm B, 10.0%) or control rates (objective responses plus stable disease) after 7 weeks (arm A, 30%; arm B, 47%) or in overall survival (arm A, 86 days; arm B, 105 days). However, there was a significant difference in favour of arm B for the time to cerebral progression (P = 0.028, Wilcoxon test). In conclusion, fotemustine plus whole brain irradiation delayed the time to cerebral progression of melanoma cerebral metastases compared with fotemustine alone but without a significant improvement in terms of objective control or overall survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI